Home » Healthcare » Pharmaceuticals » Aspergillosis Treatment Market

Aspergillosis Treatment Market Growth, Future Prospects & Competitive Analysis, 2016 – 2023

Price: $4999

Published: | Report ID: 2106 | Report Format : PDF

Market Insights

According to the Cleveland Clinic, aspergillosis is an infection or allergic reaction caused by various kinds of molds found on plants, soil, building materials, or rotting vegetables. The aspergillosis treatment market can be segmented on the basis of several types, such as allergic bronchopulmonary aspergillosis (ABPA), allergic Aspergillus sinusitis, aspergilloma, chronic pulmonary aspergillosis, invasive aspergillosis, and cutaneous (skin) aspergillosis.

ABPA is observed as one of the most common aspergillosis types in which inflammation in the lungs and allergy symptoms such as coughing and wheezing are observed. ABPA is treated with the delivery of steroids such as prednisolone through aerosol during the attacks; in some cases, itraconazole is also used to reduce the dose of steroids. ABPA usually affects people suffering from asthma and cystic fibrosis; around 1 in every 40 people with asthma may be affected by ABPA.

Invasive aspergillosis is the most severe type of aspergillosis as the infection travels from the lung to the bloodstream, infecting other organs such as the kidneys, liver, skin, or brain; it is mostly observed in people with low immunity. Invasive aspergillosis is treated with voriconazole, caspofungin, micafungin, itraconazole, amphotericin B, or posaconazole. Medical practitioners suggest that prophylactic antifungal therapy accompanied by the use of laminar airflow (LAF) or high-efficiency particulate air (HEPA) filtration in patient rooms can prevent the risk of aspergillosis, especially in patients who receive organ transplants.

The recent FDA approval received by isavuconazole (Cresemba) for invasive aspergillosis in March 2015 is considered a major boost to the aspergillosis treatment market in the near future. Approval was based on the SECURE study (n = 516) that demonstrated isavuconazole as non-inferior to voriconazole on the primary endpoint of all-cause mortality at day 42 for the treatment of adult patients with invasive aspergillosis or other filamentous fungi (isavuconazole 18.6% vs. voriconazole 20.2%). The report also suggested that isavuconazole has activity against most strains of the following microorganisms, both in vitro and in clinical infection: Aspergillus niger, Aspergillus fumigatus, and Aspergillus flavus.

The aspergillosis treatment market can be segmented on the basis of drug class, such as antifungal and corticosteroids. Antifungals can be further classified as voriconazole, itraconazole, caspofungin, micafungin, amphotericin B, and isavuconazole. The corticosteroids that are highly preferred in aspergillosis treatment are prednisolone, prednisone, and methylprednisolone. The prevalence of aspergillosis is about 1–2 per 100,000 people every year.

The global aspergillosis treatment market is segmented on the following basis:

Type of Aspergillosis

  • Allergic Bronchopulmonary Aspergillosis (ABPA)
  • Allergic Aspergillus Sinusitis
  • Aspergilloma
  • Chronic pulmonary aspergillosis
  • Invasive Aspergillosis
  • Cutaneous (skin) Aspergillosis

Type of Drug Class

  • Antifungal
  • Voriconazole
  • Itraconazole
  • Caspofungin
  • Micafungin
  • Amphotericin B
  • Isavuconazole
  • Corticosteroids
  • Prednisolone
  • Prednisone
  • Methylprednisolone


  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Key players identified for the aspergillosis treatment market include but are not limited to:

The key players in the market are Pfizer Inc., Astra Zeneca Plc, Merck & Co., GlaxoSmithKline, Mylan Pharmaceuticals, Inc., Novartis AG, Abbott Laboratories, Inc., Takeda Pharmaceutical Company Ltd., Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.), Basilea Pharmaceutica Ltd., and others.

This report offers the following:

      • An overview of the global markets for aspergillosis treatment
      • Market trends assessment for the period 2013-2023, with historical information for 2013, 2014, and 2015, and projections through 2023, with respective CAGRs during 2016-2023
      • Qualitative assessment tools such as market drivers, challenges, and opportunities
      • Market competition scrutiny tools such as market share analysis, fractal map assessment, and Porter’s Five Forces model
      • Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
      • A general overview of the industry structure
      • Company profiles highlight key information about the major players operating in the aspergillosis treatment market.

Frequently Asked Question:

What is the size of Aspergillosis Treatment Market?

The market for Aspergillosis Treatment Market is expected to reach USD$ XX in 2023.

What is the Aspergillosis Treatment Market CAGR?

The Aspergillosis Treatment Market is expected to see significant CAGR growth over the coming years, at XX%.

What is the Forecast period considered for Aspergillosis Treatment Market?

The report is forecasted from 2016 -2023.

What is the base year considered for Aspergillosis Treatment Market?

The base year of this report is 2015.

Who are the major players in this market?

Pfizer Inc., Astra Zeneca Plc, Merck & Co., GlaxoSmithKline, Mylan Pharmaceuticals, Inc., Novartis AG, Abbott Laboratories, Inc., Takeda Pharmaceutical Company Ltd .are some of the major players in the global market.

Prostate Cancer Market

Report ID: 36273

Antineoplastic Agents Market

Report ID: 36065

US Retail Pharmacy Market

Report ID: 32801

OTC Vitamins Dietary Supplements Market

Report ID: 35994

Liposomes Market

Report ID: 35888

UK Iron Supplement Market

Report ID: 35709

U.S. Iron Supplement Market

Report ID: 35688

Malignant Ascites Market

Report ID: 11184

Middle East and Africa In-Vitro Fertilization (IVF) Market

Report ID: 35578

Chronic Myeloid Leukemia (CML) Treatment Market

Report ID: 2939

Combination Therapies In Aesthetics Market

Report ID: 35434

CAR T-Cell Therapy Market

Report ID: 2051

Purchase Options

Delivery Format: Excel.
Designed for the individual purchaser.
Users located at a single corporate site or regional office.
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –


+91 6232 49 3207


24/7 Research Support


– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN